deltatrials
Completed PHASE1 INTERVENTIONAL NCT00120939

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Chemotherapy in the Treatment of Advanced Solid Tumors

Sponsor: Pharmacyclics LLC.

Conditions Breast Neoplasms Gastrointestinal Neoplasms Lung Neoplasms Ovarian Neoplasms Prostatic Neoplasms
Interventions Motexafin Gadolinium
Updated 5 times since 2017 Last updated: Apr 2, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Breast Neoplasms and Gastrointestinal Neoplasms and is currently completed. Pharmacyclics LLC. leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pharmacyclics LLC.
Data source: Pharmacyclics LLC.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations